STAT+: Pharmalittle: Cancer drug trial yields remission in every patient; Novartis data hacked by extortionists
Good morning, everyone, and welcome to another working week. We hope the weekend respite was restful and invigorating, because that oh-so familiar routine of meetings, online calls, and deadlines has predictably returned. But you knew this would happen, yes? After all, no matter how we sometimes try to slow things down, the world — such as it is — keeps spinning. So better to give it a nudge with a delightful cup of stimulation. Our choice today is the ever-so-smooth butter pecan. Feel free to join us. Meanwhile, here are a few tidbits to help you on your journey today, which we hope will be simply smashing. Best of luck and keep in touch. …
In results called unprecedented and well beyond what doctors conducting a study had expected, an experimental GSK treatment made a woman’s rectal cancer shrink until it was undetectable — and did the same for the 13 other participants in the clinical trial, all of whom had locally advanced rectal cancer, STAT reports. So far, all of them have been spared radiation, chemotherapy, and disfiguring surgery that often involves the removal of the rectum. Results from the trial were presented Sunday at the annual meeting of the American Society of Clinical Oncology and simultaneously published in the New England Journal of Medicine.
Continue to STAT+ to read the full story…
